Renasant Bank Makes New $1.02 Million Investment in Pfizer Inc. $PFE

Renasant Bank bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 41,897 shares of the biopharmaceutical company’s stock, valued at approximately $1,016,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the first quarter valued at approximately $27,000. Curio Wealth LLC raised its stake in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the second quarter worth approximately $29,000. Finally, WPG Advisers LLC bought a new stake in Pfizer during the 1st quarter valued at $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.18.

Pfizer Stock Up 4.5%

Pfizer stock opened at $25.49 on Wednesday. The firm has a 50 day moving average price of $24.75 and a 200-day moving average price of $24.41. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a market capitalization of $144.93 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.